Immunogenicity of an HPV-16 L2 DNA vaccine

Vaccine. 2009 Oct 30;27(46):6432-4. doi: 10.1016/j.vaccine.2009.06.015. Epub 2009 Jun 24.

Abstract

The ability to elicit cross-neutralizing antibodies makes human papillomavirus (HPV) L2 capsid protein a possible HPV vaccine. We examined and compared the humoral response of mice immunized with a HPV-16 L2 DNA vaccine or with HPV-16 L2 protein. The L2 DNA vaccine elicited a non-neutralizing antibody response unlike the L2 protein. L2 DNA vaccination suppressed the growth of L2-expressing C3 tumor cells, which is a T cell mediated effect, demonstrating that the lack of non-neutralizing antibody induction by L2 DNA was not caused by lack of T cell immunogenicity of the construct.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood
  • Capsid Proteins / immunology*
  • Cell Line, Tumor
  • Female
  • Human papillomavirus 16 / immunology
  • Mice
  • Mice, Inbred C57BL
  • Neutralization Tests
  • Oncogene Proteins, Viral / immunology*
  • Papillomavirus Infections / immunology
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines / immunology*
  • Vaccines, DNA / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Capsid Proteins
  • L2 protein, Human papillomavirus type 16
  • Oncogene Proteins, Viral
  • Papillomavirus Vaccines
  • Vaccines, DNA